Pathnova

Executive Summary

Pathnova Laboratories is a Singapore-based diagnostics company that has commercialized an AI-driven immunofluorescence assay (IFA) platform for nasopharyngeal cancer (NPC) and Epstein-Barr virus (EBV) detection. Its core technology combines deep learning with fuzzy inference to automate IFA analysis, delivering quantitative, interpretable results that match expert pathologists. The company’s IVD kits are ISO 13485, CAP, and HSA approved, positioning it as a validated player in the infectious disease and oncology diagnostics space. Pathnova operates under the Archerfish Precision Diagnostics holding, which suggests a broader portfolio expansion strategy. The company targets the growing demand for non-invasive, AI-enabled diagnostic solutions in Asia and beyond, addressing the high incidence of NPC in Southeast Asia. With a commercial-stage presence and regulatory approvals in Singapore, Pathnova is well-positioned to scale regionally. However, the company remains private with limited disclosed financials, and its current revenue traction is unclear. The key near-term opportunity lies in expanding its product menu beyond NPC/EBV and entering larger markets such as the US or EU, which would require additional regulatory clearances. Overall, Pathnova represents a niche but promising AI diagnostics play, with a validated technology platform and a clear unmet need in NPC screening.

Upcoming Catalysts (preview)

• Q2 2026FDA 510(k) clearance or CE marking for NPC/EBV IVD kit40% success
• Q4 2026Expansion of test menu to include other EBV-associated diseases (e.g., multiple sclerosis, lymphoma)50% success
• Q3 2026Strategic partnership or distribution agreement with a major hospital network in Southeast Asia60% success